Journal
CARDIOVASCULAR DRUG REVIEWS
Volume 25, Issue 3, Pages 221-234Publisher
WILEY
DOI: 10.1111/j.1527-3466.2007.00020.x
Keywords
E2F; intimal hyperplasia; oligonucleotides; smooth muscle cells; transcription factor decoy; vein bypass graft
Ask authors/readers for more resources
The era of genomics and recombinant DNA technology has ushered in an entirely new class of therapeutic agents designed to influence disease progression at a genetic level. The scope and utility of this technology is not fully realized. However, multiple trials of therapeutic agents have been completed and many more are ongoing. Here we report on edifoligide, a double-stranded oligodeoxynucleotide (ODN) that competitively inhibits the transcription factor E2F, a critical regulator of the cell cycle. Edifoligide has undergone extensive clinical testing for the treatment of intimal hyperplasia following vascular bypass procedures. In this review we address the rationale for targeting E2F in vascular disease, the pharmacology of edifoligide, and the results of preclinical and clinical studies using this novel compound.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available